Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Lowered by Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

HALO has been the subject of several other research reports. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Leerink Partners raised Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a research note on Tuesday, October 14th. Finally, Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Halozyme Therapeutics Stock Down 0.2%

Shares of HALO stock opened at $68.24 on Friday. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The stock has a fifty day moving average price of $70.66 and a 200 day moving average price of $62.89. The stock has a market cap of $8.02 billion, a P/E ratio of 15.62, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same quarter in the previous year, the firm posted $1.27 EPS. The business’s revenue for the quarter was up 22.1% on a year-over-year basis. Analysts predict that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total transaction of $173,594.65. Following the transaction, the chief financial officer owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the transaction, the director directly owned 44,952 shares in the company, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 108,227 shares of company stock worth $7,779,595. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently modified their holdings of the stock. Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $125,000. Redhawk Wealth Advisors Inc. grew its holdings in Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after buying an additional 4,827 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Halozyme Therapeutics by 9.9% in the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after purchasing an additional 13,789 shares during the period. Focus Partners Wealth boosted its position in shares of Halozyme Therapeutics by 57.8% during the 1st quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock valued at $7,709,000 after acquiring an additional 44,260 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in Halozyme Therapeutics by 78.0% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock valued at $5,305,000 after purchasing an additional 44,700 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.